Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EquipNet to Discuss Asset Management Systems at Interphex 2014

Published: Friday, March 14, 2014
Last Updated: Friday, March 14, 2014
Bookmark and Share
Visit EquipNet on Booth #1239.

Experts from EquipNet Inc. will be on hand at Interphex 2014 (18-20 March in New York City) to demonstrate and discuss the company’s unique asset management solution.

The industry-leading company is dedicated to the pharmaceutical, biotechnology and chemical markets; helping businesses redeploy or sell idle or surplus analytical instruments, process pilot, laboratory, and packaging equipment.

Asset management has evolved in recent years, with surveys showing companies have, on average, 5% of their assets lying idle. EquipNet has been at the forefront of these changes and now offers its clients a range of workflow and management solutions to aid redeployment or sale of business assets.

Their web-based system, ARMS™ (Asset Redeployment Management System) sits behind a company’s firewall, efficiently tracking and facilitating internally redeployment of equipment that is not being used in its current location.

Where an asset can not be relocated, it can be moved through into one of several sales channels. In every case, EquipNet specialists provide expert knowledge and proven project management skills to deliver a complete service package.

Ben Potenza, VP Marketing at EquipNet, said, “Working with both multinational enterprises as well as small and medium sized companies with a single facility, we provide our clients with options to redeploy or sell surplus plant and equipment to gain a real return on their investment.”

To find out more about EquipNet’s asset management expertise and how pharmaceutical industry companies have benefited, visit EquipNet on Booth #1239.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Chi-Med Initiates Sulfatinib Phase III Registration Study
Company has initiated SANET-p, a Phase III registration trial of sulfatinib with pancreatic neuroendocrine tumors (“NETs”).
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!